These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21283127)

  • 1. Mitosis is not a key target of microtubule agents in patient tumors.
    Komlodi-Pasztor E; Sackett D; Wilkerson J; Fojo T
    Nat Rev Clin Oncol; 2011 Feb; 8(4):244-50. PubMed ID: 21283127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.
    Komlodi-Pasztor E; Sackett DL; Fojo AT
    Clin Cancer Res; 2012 Jan; 18(1):51-63. PubMed ID: 22215906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton.
    Steinmetz MO; Prota AE
    Trends Cell Biol; 2018 Oct; 28(10):776-792. PubMed ID: 29871823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.
    Harrison MR; Holen KD; Liu G
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):54-64. PubMed ID: 19274042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
    Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
    Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ; Kanakkanthara A; Miller JH
    Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interphase microtubules: chief casualties in the war on cancer?
    Ogden A; Rida PC; Reid MD; Aneja R
    Drug Discov Today; 2014 Jul; 19(7):824-9. PubMed ID: 24201225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Too early to say, "no targeting of mitosis!".
    Kitagawa K
    Nat Rev Clin Oncol; 2011 May; 8(7):444; author reply 444. PubMed ID: 21587220
    [No Abstract]   [Full Text] [Related]  

  • 9. Target driven preclinical screening for new antimitotic chemotherapy agents.
    Novío S; Freire-Garabal M; Núñez MJ
    Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
    Fürst R; Vollmar AM
    Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
    Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA
    Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mitosis for anti-cancer therapy.
    Sudakin V; Yen TJ
    BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Development of Anti-mitotic Drugs in Cancer.
    Olziersky AM; Labidi-Galy SI
    Adv Exp Med Biol; 2017; 1002():125-152. PubMed ID: 28600785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents.
    Whitaker RH; Placzek WJ
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance.
    Ogden A; Rida PC; Reid MD; Kucuk O; Aneja R
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):277-81. PubMed ID: 25695344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.
    Risinger AL; Dybdal-Hargreaves NF; Mooberry SL
    Anticancer Res; 2015 Nov; 35(11):5845-50. PubMed ID: 26504006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer.
    Dalton WB; Yang VW
    Future Oncol; 2009 Nov; 5(9):1363-70. PubMed ID: 19903065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in mitotic inhibitors for cancer treatment.
    Jiang N; Wang X; Yang Y; Dai W
    Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do microtubule-targeted drugs work? An overview.
    Jordan MA; Kamath K
    Curr Cancer Drug Targets; 2007 Dec; 7(8):730-42. PubMed ID: 18220533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitotic drug targets.
    Kaestner P; Bastians H
    J Cell Biochem; 2010 Oct; 111(2):258-65. PubMed ID: 20518069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.